49,319 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by Paragon Capital Management Inc.

Paragon Capital Management Inc. purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 49,319 shares of the biotechnology company’s stock, valued at approximately $1,642,000. Exelixis comprises about 1.3% of Paragon Capital Management Inc.’s investment portfolio, making the stock its 23rd biggest position.

Several other institutional investors and hedge funds have also bought and sold shares of EXEL. USA Financial Formulas bought a new stake in shares of Exelixis in the 4th quarter worth approximately $32,000. V Square Quantitative Management LLC bought a new stake in shares of Exelixis in the 3rd quarter worth approximately $30,000. UMB Bank n.a. grew its position in shares of Exelixis by 68.4% in the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after buying an additional 553 shares during the last quarter. Brooklyn Investment Group bought a new stake in shares of Exelixis in the 3rd quarter worth approximately $42,000. Finally, MassMutual Private Wealth & Trust FSB grew its position in shares of Exelixis by 18.1% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock worth $63,000 after buying an additional 290 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Insider Transactions at Exelixis

In related news, EVP Jeffrey Hessekiel sold 60,000 shares of Exelixis stock in a transaction on Friday, November 29th. The stock was sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the sale, the executive vice president now owns 486,059 shares of the company’s stock, valued at $17,823,783.53. The trade was a 10.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $35.27, for a total value of $352,700.00. Following the completion of the sale, the executive vice president now directly owns 278,665 shares of the company’s stock, valued at $9,828,514.55. The trade was a 3.46 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 111,588 shares of company stock worth $3,981,864 over the last quarter. 2.85% of the stock is currently owned by insiders.

Exelixis Price Performance

EXEL stock opened at $33.12 on Wednesday. Exelixis, Inc. has a 1-year low of $20.01 and a 1-year high of $37.59. The business has a fifty day moving average price of $34.54 and a 200-day moving average price of $30.33. The stock has a market capitalization of $9.46 billion, a P/E ratio of 21.23, a P/E/G ratio of 0.72 and a beta of 0.53.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on EXEL shares. Stephens reiterated an “equal weight” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Monday, January 27th. Stifel Nicolaus lifted their price target on Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a research report on Wednesday, October 16th. The Goldman Sachs Group upgraded Exelixis to a “strong sell” rating in a research report on Tuesday, October 15th. Wells Fargo & Company lifted their price target on Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Finally, Truist Financial lifted their price target on Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.06.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.